Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 26 entries
Sorted by: Best Match Show Resources per page
Comprehensive genomic transcriptomic tumor-normal gene panel analysis for enhanced precision in patients with lung cancer.

Oncotarget

Rabizadeh S, Garner C, Sanborn JZ, Benz SC, Reddy S, Soon-Shiong P.
PMID: 29721196
Oncotarget. 2018 Apr 10;9(27):19223-19232. doi: 10.18632/oncotarget.24973. eCollection 2018 Apr 10.

A CMS approved test for lung cancer is based on tumor-only analysis of a targeted 35 gene panel, specifically excluding the use of the patient's normal germline tissue. However, this tumor-only approach increases the risk of mistakenly identifying germline...

Cite
Rabizadeh S, Garner C, Sanborn JZ, et al. Comprehensive genomic transcriptomic tumor-normal gene panel analysis for enhanced precision in patients with lung cancer. Oncotarget. 2018;9(27):19223-19232doi: 10.18632/oncotarget.24973.
Rabizadeh, S., Garner, C., Sanborn, J. Z., Benz, S. C., Reddy, S., & Soon-Shiong, P. (2018). Comprehensive genomic transcriptomic tumor-normal gene panel analysis for enhanced precision in patients with lung cancer. Oncotarget, 9(27), 19223-19232. https://doi.org/10.18632/oncotarget.24973
Rabizadeh, Shahrooz, et al. "Comprehensive genomic transcriptomic tumor-normal gene panel analysis for enhanced precision in patients with lung cancer." Oncotarget vol. 9,27 (2018): 19223-19232. doi: https://doi.org/10.18632/oncotarget.24973
Rabizadeh S, Garner C, Sanborn JZ, Benz SC, Reddy S, Soon-Shiong P. Comprehensive genomic transcriptomic tumor-normal gene panel analysis for enhanced precision in patients with lung cancer. Oncotarget. 2018 Apr 10;9(27):19223-19232. doi: 10.18632/oncotarget.24973. eCollection 2018 Apr 10. PMID: 29721196; PMCID: PMC5922390.
Copy Download .nbib Format: NLM
The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex.

Oncoimmunology

Jochems C, Tritsch SR, Knudson KM, Gameiro SR, Smalley Rumfield C, Pellom ST, Morillon YM, Newman R, Marcus W, Szeto C, Rabizadeh S, Wong HC, Soon-Shiong P, Schlom J.
PMID: 30713787
Oncoimmunology. 2018 Nov 27;8(2):e1532764. doi: 10.1080/2162402X.2018.1532764. eCollection 2019.

Here we describe a novel bifunctional fusion protein, designated N-809. This molecule comprises the IL-15/IL15Rα superagonist complex containing the Fc-domain of IgG1 (N-803, formerly designated as ALT-803) fused to two single chain anti-PD-L1 domains. The fully human IgG1 portion...

Cite
Jochems C, Tritsch SR, Knudson KM, et al. The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex. Oncoimmunology. 2018;8(2):e1532764doi: 10.1080/2162402X.2018.1532764.
Jochems, C., Tritsch, S. R., Knudson, K. M., Gameiro, S. R., Smalley Rumfield, C., Pellom, S. T., Morillon, Y. M., Newman, R., Marcus, W., Szeto, C., Rabizadeh, S., Wong, H. C., Soon-Shiong, P., & Schlom, J. (2019). The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex. Oncoimmunology, 8(2), e1532764. https://doi.org/10.1080/2162402X.2018.1532764
Jochems, Caroline, et al. "The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex." Oncoimmunology vol. 8,2 (2019): e1532764. doi: https://doi.org/10.1080/2162402X.2018.1532764
Jochems C, Tritsch SR, Knudson KM, Gameiro SR, Smalley Rumfield C, Pellom ST, Morillon YM, Newman R, Marcus W, Szeto C, Rabizadeh S, Wong HC, Soon-Shiong P, Schlom J. The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex. Oncoimmunology. 2018 Nov 27;8(2):e1532764. doi: 10.1080/2162402X.2018.1532764. eCollection 2019. PMID: 30713787; PMCID: PMC6343815.
Copy Download .nbib Format: NLM
Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.

Blood

Berrien-Elliott MM, Becker-Hapak M, Cashen AF, Jacobs MT, Wong P, Foster M, McClain E, Desai S, Pence P, Cooley S, Brunstein CG, Gao F, Abboud CN, Uy GL, Westervelt P, Jacoby MA, Pusic I, Stockerl-Goldstein K, Schroeder MA, DiPersio JF, Soon-Shiong P, Miller JS, Fehniger TA.
PMID: 34797911
Blood. 2021 Nov 19; doi: 10.1182/blood.2021011532. Epub 2021 Nov 19.

NK cells are a promising alternative to T cells for cancer immunotherapy. Adoptive therapies with allogeneic, cytokine-activated NK cells are being investigated in clinical trials. However, the optimal cytokine support after adoptive transfer to promote NK cell expansion, and...

Cite
Berrien-Elliott MM, Becker-Hapak M, Cashen AF, et al. Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. Blood. 2021;doi: 10.1182/blood.2021011532.
Berrien-Elliott, M. M., Becker-Hapak, M., Cashen, A. F., Jacobs, M. T., Wong, P., Foster, M., McClain, E., Desai, S., Pence, P., Cooley, S., Brunstein, C. G., Gao, F., Abboud, C. N., Uy, G. L., Westervelt, P., Jacoby, M. A., Pusic, I., Stockerl-Goldstein, K., Schroeder, M. A., DiPersio, J. F., Soon-Shiong, P., Miller, J. S., & Fehniger, T. A. (2021). Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. Blood, . https://doi.org/10.1182/blood.2021011532
Berrien-Elliott, Melissa M, et al. "Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy." Blood vol. (2021). doi: https://doi.org/10.1182/blood.2021011532
Berrien-Elliott MM, Becker-Hapak M, Cashen AF, Jacobs MT, Wong P, Foster M, McClain E, Desai S, Pence P, Cooley S, Brunstein CG, Gao F, Abboud CN, Uy GL, Westervelt P, Jacoby MA, Pusic I, Stockerl-Goldstein K, Schroeder MA, DiPersio JF, Soon-Shiong P, Miller JS, Fehniger TA. Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. Blood. 2021 Nov 19; doi: 10.1182/blood.2021011532. Epub 2021 Nov 19. PMID: 34797911.
Copy Download .nbib Format: NLM
Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy.

Journal for immunotherapy of cancer

Reimann H, Nguyen A, Sanborn JZ, Vaske CJ, Benz SC, Niazi K, Rabizadeh S, Spilman P, Mackensen A, Ruebner M, Hein A, Beckmann MW, van der Meijden ED, Bausenwein J, Kretschmann S, Griffioen M, Schlom J, Gulley JL, Lee KL, Hamilton DH, Soon-Shiong P, Fasching PA, Kremer AN.
PMID: 34172517
J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2021-002605.

BACKGROUND: Therapeutic regimens designed to augment the immunological response of a patient with breast cancer (BC) to tumor tissue are critically informed by tumor mutational burden and the antigenicity of expressed neoepitopes. Herein we describe a neoepitope and cognate...

Cite
Reimann H, Nguyen A, Sanborn JZ, et al. Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy. J Immunother Cancer. 2021;9(6)doi: 10.1136/jitc-2021-002605.
Reimann, H., Nguyen, A., Sanborn, J. Z., Vaske, C. J., Benz, S. C., Niazi, K., Rabizadeh, S., Spilman, P., Mackensen, A., Ruebner, M., Hein, A., Beckmann, M. W., van der Meijden, E. D., Bausenwein, J., Kretschmann, S., Griffioen, M., Schlom, J., Gulley, J. L., Lee, K. L., Hamilton, D. H., Soon-Shiong, P., Fasching, P. A., & Kremer, A. N. (2021). Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy. Journal for immunotherapy of cancer, 9(6), . https://doi.org/10.1136/jitc-2021-002605
Reimann, Hannah, et al. "Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy." Journal for immunotherapy of cancer vol. 9,6 (2021). doi: https://doi.org/10.1136/jitc-2021-002605
Reimann H, Nguyen A, Sanborn JZ, Vaske CJ, Benz SC, Niazi K, Rabizadeh S, Spilman P, Mackensen A, Ruebner M, Hein A, Beckmann MW, van der Meijden ED, Bausenwein J, Kretschmann S, Griffioen M, Schlom J, Gulley JL, Lee KL, Hamilton DH, Soon-Shiong P, Fasching PA, Kremer AN. Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy. J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2021-002605. PMID: 34172517; PMCID: PMC8237736.
Copy Download .nbib Format: NLM
Graphene nanoplatelet and graphene oxide functionalization of face mask materials inhibits infectivity of trapped SARS-CoV-2.

iScience

De Maio F, Palmieri V, Babini G, Augello A, Palucci I, Perini G, Salustri A, Spilman P, De Spirito M, Sanguinetti M, Delogu G, Rizzi LG, Cesareo G, Soon-Shiong P, Sali M, Papi M.
PMID: 34222841
iScience. 2021 Jul 23;24(7):102788. doi: 10.1016/j.isci.2021.102788. Epub 2021 Jun 25.

Recent advancements in bidimensional nanoparticles production such as graphene (G) and graphene oxide (GO) have the potential to meet the need for highly functional personal protective equipment (PPE) against SARS-CoV-2 infection. The ability of G and GO to interact...

Cite
De Maio F, Palmieri V, Babini G, et al. Graphene nanoplatelet and graphene oxide functionalization of face mask materials inhibits infectivity of trapped SARS-CoV-2. iScience. 2021;24(7):102788doi: 10.1016/j.isci.2021.102788.
De Maio, F., Palmieri, V., Babini, G., Augello, A., Palucci, I., Perini, G., Salustri, A., Spilman, P., De Spirito, M., Sanguinetti, M., Delogu, G., Rizzi, L. G., Cesareo, G., Soon-Shiong, P., Sali, M., & Papi, M. (2021). Graphene nanoplatelet and graphene oxide functionalization of face mask materials inhibits infectivity of trapped SARS-CoV-2. iScience, 24(7), 102788. https://doi.org/10.1016/j.isci.2021.102788
De Maio, Flavio, et al. "Graphene nanoplatelet and graphene oxide functionalization of face mask materials inhibits infectivity of trapped SARS-CoV-2." iScience vol. 24,7 (2021): 102788. doi: https://doi.org/10.1016/j.isci.2021.102788
De Maio F, Palmieri V, Babini G, Augello A, Palucci I, Perini G, Salustri A, Spilman P, De Spirito M, Sanguinetti M, Delogu G, Rizzi LG, Cesareo G, Soon-Shiong P, Sali M, Papi M. Graphene nanoplatelet and graphene oxide functionalization of face mask materials inhibits infectivity of trapped SARS-CoV-2. iScience. 2021 Jul 23;24(7):102788. doi: 10.1016/j.isci.2021.102788. Epub 2021 Jun 25. PMID: 34222841; PMCID: PMC8233064.
Copy Download .nbib Format: NLM
Deep Learning Implicitly Handles Tissue Specific Phenomena to Predict Tumor DNA Accessibility and Immune Activity.

iScience

Wnuk K, Sudol J, Givechian KB, Soon-Shiong P, Rabizadeh S, Szeto C, Vaske C.
PMID: 31563852
iScience. 2019 Oct 25;20:119-136. doi: 10.1016/j.isci.2019.09.018. Epub 2019 Sep 14.

DNA accessibility is a key dynamic feature of chromatin regulation that can potentiate transcriptional events and tumor progression. To gain insight into chromatin state across existing tumor data, we improved neural network models for predicting accessibility from DNA sequence...

Cite
Wnuk K, Sudol J, Givechian KB, et al. Deep Learning Implicitly Handles Tissue Specific Phenomena to Predict Tumor DNA Accessibility and Immune Activity. iScience. 2019;20:119-136doi: 10.1016/j.isci.2019.09.018.
Wnuk, K., Sudol, J., Givechian, K. B., Soon-Shiong, P., Rabizadeh, S., Szeto, C., & Vaske, C. (2019). Deep Learning Implicitly Handles Tissue Specific Phenomena to Predict Tumor DNA Accessibility and Immune Activity. iScience, 20119-136. https://doi.org/10.1016/j.isci.2019.09.018
Wnuk, Kamil, et al. "Deep Learning Implicitly Handles Tissue Specific Phenomena to Predict Tumor DNA Accessibility and Immune Activity." iScience vol. 20 (2019): 119-136. doi: https://doi.org/10.1016/j.isci.2019.09.018
Wnuk K, Sudol J, Givechian KB, Soon-Shiong P, Rabizadeh S, Szeto C, Vaske C. Deep Learning Implicitly Handles Tissue Specific Phenomena to Predict Tumor DNA Accessibility and Immune Activity. iScience. 2019 Oct 25;20:119-136. doi: 10.1016/j.isci.2019.09.018. Epub 2019 Sep 14. PMID: 31563852; PMCID: PMC6823659.
Copy Download .nbib Format: NLM
Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition.

Journal for immunotherapy of cancer

Fenerty KE, Padget M, Wolfson B, Gameiro SR, Su Z, Lee JH, Rabizadeh S, Soon-Shiong P, Hodge JW.
PMID: 30486888
J Immunother Cancer. 2018 Nov 29;6(1):133. doi: 10.1186/s40425-018-0445-4.

BACKGROUND: Poly (ADP-ribose) polymerase inhibitors (PARPi) prevent single-stranded DNA repair. Olaparib is a PARPi approved for the treatment of BRCA mutant ovarian and breast carcinoma. Emerging clinical data suggest a benefit of combining olaparib with immunotherapy in prostate cancer...

Cite
Fenerty KE, Padget M, Wolfson B, et al. Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition. J Immunother Cancer. 2018;6(1):133doi: 10.1186/s40425-018-0445-4.
Fenerty, K. E., Padget, M., Wolfson, B., Gameiro, S. R., Su, Z., Lee, J. H., Rabizadeh, S., Soon-Shiong, P., & Hodge, J. W. (2018). Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition. Journal for immunotherapy of cancer, 6(1), 133. https://doi.org/10.1186/s40425-018-0445-4
Fenerty, Kathleen E, et al. "Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition." Journal for immunotherapy of cancer vol. 6,1 (2018): 133. doi: https://doi.org/10.1186/s40425-018-0445-4
Fenerty KE, Padget M, Wolfson B, Gameiro SR, Su Z, Lee JH, Rabizadeh S, Soon-Shiong P, Hodge JW. Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition. J Immunother Cancer. 2018 Nov 29;6(1):133. doi: 10.1186/s40425-018-0445-4. PMID: 30486888; PMCID: PMC6264611.
Copy Download .nbib Format: NLM
CAD/POLD2 gene expression is associated with poor overall survival and chemoresistance in bladder urothelial carcinoma.

Oncotarget

Givechian KB, Garner C, Garban H, Rabizadeh S, Soon-Shiong P.
PMID: 30038717
Oncotarget. 2018 Jul 03;9(51):29743-29752. doi: 10.18632/oncotarget.25701. eCollection 2018 Jul 03.

Somatic mutations in DNA repair genes have been clinically associated with chemosensitivity, although few studies have interrogated the nucleotide synthesis pathways that supply DNA repair processes. Previous work suggests that bladder urothelial carcinoma is uniquely enriched for mutations in...

Cite
Givechian KB, Garner C, Garban H, et al. CAD/POLD2 gene expression is associated with poor overall survival and chemoresistance in bladder urothelial carcinoma. Oncotarget. 2018;9(51):29743-29752doi: 10.18632/oncotarget.25701.
Givechian, K. B., Garner, C., Garban, H., Rabizadeh, S., & Soon-Shiong, P. (2018). CAD/POLD2 gene expression is associated with poor overall survival and chemoresistance in bladder urothelial carcinoma. Oncotarget, 9(51), 29743-29752. https://doi.org/10.18632/oncotarget.25701
Givechian, Kevin B, et al. "CAD/POLD2 gene expression is associated with poor overall survival and chemoresistance in bladder urothelial carcinoma." Oncotarget vol. 9,51 (2018): 29743-29752. doi: https://doi.org/10.18632/oncotarget.25701
Givechian KB, Garner C, Garban H, Rabizadeh S, Soon-Shiong P. CAD/POLD2 gene expression is associated with poor overall survival and chemoresistance in bladder urothelial carcinoma. Oncotarget. 2018 Jul 03;9(51):29743-29752. doi: 10.18632/oncotarget.25701. eCollection 2018 Jul 03. PMID: 30038717; PMCID: PMC6049856.
Copy Download .nbib Format: NLM
Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma.

Clinical cancer research : an official journal of the American Association for Cancer Research

Foltz JA, Hess BT, Bachanova V, Bartlett NL, Berrien-Elliott MM, McClain E, Becker-Hapak M, Foster M, Schappe T, Kahl B, Mehta-Shah N, Cashen AF, Marin ND, McDaniels K, Moreno C, Mosior M, Gao F, Griffith OL, Griffith M, Wagner JA, Epperla N, Rock AD, Lee J, Petti AA, Soon-Shiong P, Fehniger TA.
PMID: 33832946
Clin Cancer Res. 2021 Jun 15;27(12):3339-3350. doi: 10.1158/1078-0432.CCR-20-4575. Epub 2021 Apr 08.

PURPOSE: N-803 is an IL15 receptor superagonist complex, designed to optimize PATIENTS AND METHODS: Relapsed/refractory patients with indolent non-Hodgkin lymphoma were treated with rituximab and intravenous or subcutaneous N-803 on an open-label, dose-escalation phase I study using a 3+3...

Cite
Foltz JA, Hess BT, Bachanova V, et al. Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. Clin Cancer Res. 2021;27(12):3339-3350doi: 10.1158/1078-0432.CCR-20-4575.
Foltz, J. A., Hess, B. T., Bachanova, V., Bartlett, N. L., Berrien-Elliott, M. M., McClain, E., Becker-Hapak, M., Foster, M., Schappe, T., Kahl, B., Mehta-Shah, N., Cashen, A. F., Marin, N. D., McDaniels, K., Moreno, C., Mosior, M., Gao, F., Griffith, O. L., Griffith, M., Wagner, J. A., Epperla, N., Rock, A. D., Lee, J., Petti, A. A., Soon-Shiong, P., & Fehniger, T. A. (2021). Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(12), 3339-3350. https://doi.org/10.1158/1078-0432.CCR-20-4575
Foltz, Jennifer A, et al. "Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,12 (2021): 3339-3350. doi: https://doi.org/10.1158/1078-0432.CCR-20-4575
Foltz JA, Hess BT, Bachanova V, Bartlett NL, Berrien-Elliott MM, McClain E, Becker-Hapak M, Foster M, Schappe T, Kahl B, Mehta-Shah N, Cashen AF, Marin ND, McDaniels K, Moreno C, Mosior M, Gao F, Griffith OL, Griffith M, Wagner JA, Epperla N, Rock AD, Lee J, Petti AA, Soon-Shiong P, Fehniger TA. Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. Clin Cancer Res. 2021 Jun 15;27(12):3339-3350. doi: 10.1158/1078-0432.CCR-20-4575. Epub 2021 Apr 08. PMID: 33832946; PMCID: PMC8197753.
Copy Download .nbib Format: NLM
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.

Journal for immunotherapy of cancer

Lee MY, Robbins Y, Sievers C, Friedman J, Abdul Sater H, Clavijo PE, Judd N, Tsong E, Silvin C, Soon-Shiong P, Padget MR, Schlom J, Hodge J, Hinrichs C, Allen C.
PMID: 33741731
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-002128.

BACKGROUND: As heterogeneous tumors develop in the face of intact immunity, tumor cells harboring genomic or expression defects that favor evasion from T-cell detection or elimination are selected. For patients with such tumors, T cell-based immunotherapy alone infrequently results...

Cite
Lee MY, Robbins Y, Sievers C, et al. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells. J Immunother Cancer. 2021;9(3)doi: 10.1136/jitc-2020-002128.
Lee, M. Y., Robbins, Y., Sievers, C., Friedman, J., Abdul Sater, H., Clavijo, P. E., Judd, N., Tsong, E., Silvin, C., Soon-Shiong, P., Padget, M. R., Schlom, J., Hodge, J., Hinrichs, C., & Allen, C. (2021). Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells. Journal for immunotherapy of cancer, 9(3), . https://doi.org/10.1136/jitc-2020-002128
Lee, Maxwell Y, et al. "Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells." Journal for immunotherapy of cancer vol. 9,3 (2021). doi: https://doi.org/10.1136/jitc-2020-002128
Lee MY, Robbins Y, Sievers C, Friedman J, Abdul Sater H, Clavijo PE, Judd N, Tsong E, Silvin C, Soon-Shiong P, Padget MR, Schlom J, Hodge J, Hinrichs C, Allen C. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells. J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-002128. PMID: 33741731; PMCID: PMC7986659.
Copy Download .nbib Format: NLM
Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma.

Clinical cancer research : an official journal of the American Association for Cancer Research

Foltz JA, Hess BT, Bachanova V, Bartlett NL, Berrien-Elliott MM, McClain E, Becker-Hapak M, Foster M, Schappe T, Kahl B, Mehta-Shah N, Cashen AF, Marin ND, McDaniels K, Moreno C, Mosior M, Gao F, Griffith OL, Griffith M, Wagner JA, Epperla N, Rock AD, Lee J, Petti AA, Soon-Shiong P, Fehniger TA.
PMID: 33832946
Clin Cancer Res. 2021 Jun 15;27(12):3339-3350. doi: 10.1158/1078-0432.CCR-20-4575. Epub 2021 Apr 08.

PURPOSE: N-803 is an IL15 receptor superagonist complex, designed to optimize PATIENTS AND METHODS: Relapsed/refractory patients with indolent non-Hodgkin lymphoma were treated with rituximab and intravenous or subcutaneous N-803 on an open-label, dose-escalation phase I study using a 3+3...

Cite
Foltz JA, Hess BT, Bachanova V, et al. Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. Clin Cancer Res. 2021;27(12):3339-3350doi: 10.1158/1078-0432.CCR-20-4575.
Foltz, J. A., Hess, B. T., Bachanova, V., Bartlett, N. L., Berrien-Elliott, M. M., McClain, E., Becker-Hapak, M., Foster, M., Schappe, T., Kahl, B., Mehta-Shah, N., Cashen, A. F., Marin, N. D., McDaniels, K., Moreno, C., Mosior, M., Gao, F., Griffith, O. L., Griffith, M., Wagner, J. A., Epperla, N., Rock, A. D., Lee, J., Petti, A. A., Soon-Shiong, P., & Fehniger, T. A. (2021). Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(12), 3339-3350. https://doi.org/10.1158/1078-0432.CCR-20-4575
Foltz, Jennifer A, et al. "Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,12 (2021): 3339-3350. doi: https://doi.org/10.1158/1078-0432.CCR-20-4575
Foltz JA, Hess BT, Bachanova V, Bartlett NL, Berrien-Elliott MM, McClain E, Becker-Hapak M, Foster M, Schappe T, Kahl B, Mehta-Shah N, Cashen AF, Marin ND, McDaniels K, Moreno C, Mosior M, Gao F, Griffith OL, Griffith M, Wagner JA, Epperla N, Rock AD, Lee J, Petti AA, Soon-Shiong P, Fehniger TA. Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. Clin Cancer Res. 2021 Jun 15;27(12):3339-3350. doi: 10.1158/1078-0432.CCR-20-4575. Epub 2021 Apr 08. PMID: 33832946; PMCID: PMC8197753.
Copy Download .nbib Format: NLM
Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2.

Journal for immunotherapy of cancer

Chu Y, Nayyar G, Jiang S, Rosenblum JM, Soon-Shiong P, Safrit JT, Lee DA, Cairo MS.
PMID: 34244307
J Immunother Cancer. 2021 Jul;9(7). doi: 10.1136/jitc-2020-002267.

BACKGROUND: Children with recurrent and/or metastatic osteosarcoma (OS), neuroblastoma (NB) and glioblastoma multiforme (GBM) have a dismal event-free survival (

Cite
Chu Y, Nayyar G, Jiang S, et al. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2. J Immunother Cancer. 2021;9(7)doi: 10.1136/jitc-2020-002267.
Chu, Y., Nayyar, G., Jiang, S., Rosenblum, J. M., Soon-Shiong, P., Safrit, J. T., Lee, D. A., & Cairo, M. S. (2021). Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2. Journal for immunotherapy of cancer, 9(7), . https://doi.org/10.1136/jitc-2020-002267
Chu, Yaya, et al. "Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2." Journal for immunotherapy of cancer vol. 9,7 (2021). doi: https://doi.org/10.1136/jitc-2020-002267
Chu Y, Nayyar G, Jiang S, Rosenblum JM, Soon-Shiong P, Safrit JT, Lee DA, Cairo MS. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2. J Immunother Cancer. 2021 Jul;9(7). doi: 10.1136/jitc-2020-002267. PMID: 34244307; PMCID: PMC8268924.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 26 entries